FilingsTodayDaehanPharmaceutical
At a glance
DaehanPharmaceutical filed 39 disclosures in the last 12 months, including 25 insider and 2 5% holder. The most recent key filing was on Oct 30: Chairman bought 1,450 sh on the market at an average ₩25,100, Oct 26–30.
Revenue for 2025 was ₩209B, up 2.2% on 2024. Operating margin was 14.9% against 18.6% a year earlier. Debt was 16% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩109B and operating profit of ₩15.9B.
The 2025 annual report lists 737 employees with an average tenure of 10.9 years and average pay of ₩61.9M, #881 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩164M each on average. It paid ₩1,000 per common share in cash dividends, against ₩900 a year earlier (+11.1%). 이윤우 and related parties held 39.40% at year end.
From the 2025 annual report
Staff: 737 (376 men, 361 women), of whom 49 on fixed-term contracts. Total pay for the year: ₩45.6B. Directors and auditors: 5, paid ₩820M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩1,000 | ₩900 | ₩750 |
| Payout ratio | 21.3% | 15.7% | 15.5% |
| Yield (as filed) | 3.30% | 3.40% | 2.70% |
| Total cash dividends | ₩5.9B | ₩5.3B | ₩4.4B |
Largest shareholder
이윤우 holds 24.41%; with 9 related parties the group holds 39.40% of common shares at year end (from 39.37% at the start of the year).
Auditor: 서우회계법인 · opinion: Unqualified.
Rankings: Low debt #87 of 1,372
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.